logo-loader
Netscientific PLC

PDS merger with Edge Therapeutics update

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .p{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.p{}p.y{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}p.z{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align: center}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.u{font-size:10.0pt;line-height:107%;font-family:"Arial","sans-serif"; color:black}table.aa{margin-left:-5.4pt;border-collapse:collapse}td.s{width:307.9pt;padding:0cm 5.4pt 0cm 5.4pt}p.ab{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}td.r{width:121.3pt;padding:0cm 5.4pt 0cm 5.4pt} /**/
RNS Number : 2254T
NetScientific PLC
19 March 2019
 

NetScientific plc

("NetScientific" or the "Company")

PDS merger with Edge Therapeutics update

 

Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation ("PDS"), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of $10 values NetScientific's holding in PDS at £4,081,451*. It is the Company's intention to hold the shares and to make a decision on its position in due course.

*Using a US:GBP exchange rate of 1.33

 

#  #  #

For more information, please contact:

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO    

                   

Tel: +44 (0)20 3514 1800

WH Ireland Limited (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave

 

Tel: +44 (0)20 7220 1666

 

Consilium Strategic Communications            

Mary-Jane Elliott / Chris Welsh / Laura Thornton

[email protected]

Tel: +44 (0)20 3709 5700

 

 

About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCKMGMFMRFGLZZ

Quick facts: Netscientific PLC

Price: £0.07

Market: AIM
Market Cap: £5.3 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19